Analysts Conflicted on These Healthcare Names: Amgen (AMGN) and Healthequity (HQY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN) and Healthequity (HQY).
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen (AMGN)
In a report released yesterday, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Amgen, with a price target of $350.00. The company’s shares closed last Wednesday at $349.81.
According to TipRanks.com, Gould is a 4-star analyst with an average return of
Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $367.45, implying a 6.3% upside from current levels. In a report issued on March 30, Bernstein also maintained a Hold rating on the stock with a $335.00 price target.
See today’s best-performing stocks on TipRanks >>
Healthequity (HQY)
In a report released today, Sean Dodge from BMO Capital upgraded Healthequity to Buy, with a price target of $105.00. The company’s shares closed last Wednesday at $81.95.
According to TipRanks.com, Dodge is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Healthequity has an analyst consensus of Strong Buy, with a price target consensus of $113.09, a 37.2% upside from current levels. In a report issued on March 25, Barclays also maintained a Buy rating on the stock with a $110.00 price target.
Read More on AMGN:
